Genmab AS (NAS:GMAB)
$ 23.12 -0.02 (-0.09%) Market Cap: 14.68 Bil Enterprise Value: 12.55 Bil PE Ratio: 19.09 PB Ratio: 3.24 GF Score: 88/100

Q2 2020 Genmab A/S Earnings Call Transcript

Aug 12, 2020 / 04:00PM GMT
Release Date Price: $36.38 (+1.42%)
Operator

During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under an obligation to update statements regarding the future nor to confirm such statements in relation to actual results unless this is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

And now without further delay, I would like to hand the conference over to our speaker today, Jan van de Winkel. Please go ahead, Jan.

Jan G. J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

So hello, and welcome to the Genmab conference call to discuss the company's financial results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot